The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Pericardial adverse events associated with BTKis in CLL: insights from two landmark trials
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, discusses a study investigating pericardial adverse events (AEs) associated with BTK inhibitors (BTKis), particularly ibrutinib, for chronic lymphocytic leukemia (CLL). The study highlighted an increase in pericardial events in patients treated with ibrutinib compared to those receiving chemoimmunotherapy, indicating a need for clinical awareness despite these side effects being uncommon. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There is actually a lot of research that has been done looking at cardiotoxicity with BTK inhibitors especially with ibrutinib, the first generation BTK inhibitor. One of the side effects that has been far less reported are pericardial side effects, things like pericarditis, even up to tamponade. So for this study we looked at pericardial events on the AL41202 study of ibrutinib or ibrutinib plus rituximab in older adults, as well as the E1912 study of ibrutinib plus rituximab in younger adults, all as frontline treatment...
There is actually a lot of research that has been done looking at cardiotoxicity with BTK inhibitors especially with ibrutinib, the first generation BTK inhibitor. One of the side effects that has been far less reported are pericardial side effects, things like pericarditis, even up to tamponade. So for this study we looked at pericardial events on the AL41202 study of ibrutinib or ibrutinib plus rituximab in older adults, as well as the E1912 study of ibrutinib plus rituximab in younger adults, all as frontline treatment. And we did see a small, but I think significant increase in pericardial events in those patients treated with ibrutinib regimens when compared to the chemoimmunotherapy control arms, suggesting that this is in fact a real side effect that we need to be monitoring for. That being said, it is very uncommon. So while it’s something that we should be asking questions about and being clinically aware of, it’s probably not something that we need to be using as a reason to determine a therapy.
Read more...
Disclosures
Consultancy: Newave, Loxo, Beigene, AstraZeneca, Abbvie, Janssen, Pharmacyclics; Research Funding; Schrodinger, Morphosys, Karyopharm, Janssen, Pharmacyclics.
